Slide 1: Results Presentation for the Full Year Ended 30 June 2024
For immediate release 13 August 2024 RESULTS PRESENTATION FOR THE FULL YEAR ENDED 30 JUNE 2024 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer
Slide 2: 2024 Full Year Results
2024 Full Year Results Driven by Our Promise 13 August 2024
Slide 3: Important Notice and Disclaimer
Zahra K. IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to
Slide 4: Paul McKenzie CEO & Managing Director
CEO Overview Financials Outlook CEO Overview Paul McKenzie CEO & Managing Director 3
Slide 5: Delivered on Strategic Priorities in FY24
Delivered on Strategic Priorities in FY24 CSL Behring CSL Seqirus CSL Vifor Strong growth, driven by Ig Differentiated portfolio Drive synergies 14% (Ig 20%)1 Market outperformance $100m+ p.a. Rika Rollout Yield Initiatives CSL Behring gross margin Geographic Expansion 84 Centres Horizon 1 and 2 HEM
Slide 6: Strong Performance
CEO Overview Financials Outlook Strong Performance1 CSL Behring Strong growth across the portfolio driven by Ig Revenue +11% • • Ig +20%, HAEGARDA® +12%, ALBUMIN® +12%, IDELVION® +10% Gross margin +120 bps at CC NPATA2,3 +15% • Rika deployment on schedule for end-FY25 • I-Nomogram FDA clearance NPAT
Slide 7: CSL Behring Revenue $10,608m +14%
CEO Overview Financials Outlook Revenue $10,608m +14%1 Therapy Revenue ($m) Change1 Performance Major Brands • Strong performance across all geographies – PRIVIGEN® / INTRAGAM®+21%, HIZENTRA® +19% Ig 5,666 +20% • Significant patient demand in core indications • HIZENTRA® remains clear market leader
Slide 8: Operational Highlights
CEO Overview Financials Outlook Operational Highlights • Underlying fundamentals of plasma collection remain strong: ‒ Plasma donation growth momentum Rika Plasma Donation System maintained ‒ Continued reduction in CPL • Successfully rolled out to 84 centres ‒ Expanding geographic footprint • On tra
Slide 9: CSL Seqirus Revenue $2,128m +4%
CEO Overview Financials Outlook Revenue $2,128m +4%1 Therapy Revenue ($m) Change1 Performance Major Brands • Revenue growth in the northern hemisphere influenza Egg Based 140 (2%) market during a challenging season • Heightened recognition of benefits of differentiated Cell Culture 535 (11%) product
Slide 10: Operational Highlights
CEO Overview Financials Outlook Operational Highlights Seasonal Influenza Products Product Innovation Pandemic Influenza • FLUCELVAX® 6-month+ age extension • Phase III clinical study commenced for • UK Advance Purchase Agreement approved in EU, UK, Australia and New aTIVc awarded solely to CSL Seqi
Slide 11: CSL Vifor Revenue $2,064m
CEO Overview Financials Outlook Revenue $2,064m Therapy Revenue ($m) Performance Major Brands • Robust volume growth in evolving iron market Iron 1,018 – China FERINJECT® launch – US step edit pressure • MIRCERA® – Strong ESA performance as US patient conversion a continued Nephrology: • KAPRUVIA® 7
Slide 12: Financials - Joy Linton CFO
CEO Overview Financials Outlook Financials Joy Linton CFO 11
Slide 13: NPATA
CEO Overview Financials Outlook NPATA2,3 FY23 FY24 Change $3,008m Rep4 @ CC %1 $101m FX NPATA $2,610m $3,008m +15% Acquired intellectual ($235m) ($298m) property amortisation $2,907m Acquisition related ($353m) ($83m) adjustments Tax $85m $59m NPATA Attributable to NCI $137m $132m $2,610m NPAT $2,24
Slide 14: CSL Behring Financial Highlights and Gross Margin Recovery
CEO Overview Financials Outlook Segment Financial Highlights Path to Gross Margin Recovery CSL Behring • Optimise donor fees Change CPL Reduction • RIKA benefits 1 US$ millions reported FY23 FY24 % at CC • Centre efficiencies Sales 8,968 10,334 15% • HEMGENIX® Other Revenue 322 274 (15%) New Product
Slide 15: Financial Highlights: CSL Seqirus and CSL Vifor
CEO Overview Financials Outlook Segment Financial Highlights CSL Seqirus CSL Vifor Change 1 US$ millions reported FY23 FY24 % at CC US$ millions reported FY234 FY24 Sales 1,851 1,896 1% Sales 1,957 2,029 Other Revenue 180 232 28% Other Revenue 32 35 Total Revenue 2,031 2,128 4% Total Revenue 1,989 2
Slide 16: CSL Group Financial Highlights
CEO Overview Financials Outlook CSL Group Financial Highlights R&D • Growth in line with sales FY23 FY24 FY24 Change • FY25 R&D expenditure ~10% of revenue 1 1 US$ Millions Rep Rep at CC % G&A Total Revenue 13,310 14,800 14,744 11% • Efficiencies driven by centralisation of Gross Profit5 7,231 8,006
Slide 17: Capital Expenditure
CEO Overview Financials Outlook Capital Expenditure Delivering capital-efficient growth US$m % of Revenue 1,400 14% • Reduction in capex follows a period of significant capacity expansion required to 1,200 12% meet increasing market demand 1,000 10% • Prioritising yield initiatives for majority of s
Slide 18: Cash Conversion Cycle
CEO Overview Financials Outlook Cash Conversion Cycle Focus on working capital efficiency Days 250 • Cash conversion has improved from pandemic-driven peak 215 • Increase in FY24 due to timing of trade receivables 201 192 199 200 196 186 187 • Working capital efficiency is a strategic 10 year averag
Slide 19: Outlook - Paul McKenzie
CEO Overview Financials Outlook Outlook Paul McKenzie CEO & Managing Director 18
Slide 20: FY25 Outlook
FY25 Outlook CSL Behring CSL Seqirus • Underlying patient demand for • Continued market outperformance from Ig in core indications remains differentiated portfolio strong • sa-mRNA COVID vaccine development • Positive reimbursement • Commercialisation of KOSTAIVE® in Japan decisions support HEMGENIX
Slide 21: CSL Contacts
CSL Contacts Chris Cooper Investor Relations +61 455 022 740 chris.cooper@csl.com.au Bernard Ronchi Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Investor Relations +61 402 231 696 stephen.mckeon@csl.com.au
Slide 22: Notes
Notes (#) Constant currency removes the impact of exchange Summary NPAT attributable to members Summary Revenue rate movements to facilitate comparability of operational of parent entity Reported revenue $14,800m performance for the Group. This is done in three parts: a) Reported net profit after ta
Slide 23: Appendix
Appendix 22
Slide 24: CSL Behring – Key Products
Appendix A CSL Behring – Key Products CSL Behring Therapy Group Sales $m Change1 % FY24 Revenue By Therapy Group $m Privigen IVIG 3,624 27% IVIG $3,705 35% Hizentra SCIG 1,961 19% SCIG $1,961 18% Albumin Albumin 1,209 12% CSL Albumin $1,209 11% Idelvion Haemophilia 777 10% Behring Recombinants Coag
Slide 25: CSL Seqirus & CSL Vifor – Key Products
Appendix B CSL Seqirus & CSL Vifor – Key Products FY24 Revenue By Therapy Group $m CSL Seqirus Therapy Group Sales $m Change1 % Cell Culture $535 25% Fluad Adjuvanted 1,040 14% Adjuvanted $1,040 49% Flucelvax Cell culture 535 (11%) Egg Based $140 7% CSL Afluria Egg-based 140 (2%) Seqirus In License
Slide 26: Significant progress made with CSL's Sustainability Strategy
Significant progress made with CSL’s Sustainability Strategy Moving to 100% renewable Sustainability strategy refreshed electricity in Australia and • Repositioned with focus on Europe healthier communities and healthier environment • All Australian facilities from Jan 2025 • Strong progress on Scop